Antidepressant-like activity of 2-(4-phenylpiperazin-1-yl)-1, 8-naphthyridine-3-carboxylic acid (7a), a 5-HT3 receptor antagonist in behaviour based rodent models: Evidence for the involvement of serotonergic system

被引:17
|
作者
Gautam, Baldev Kumar [1 ]
Jindal, Ankur [1 ]
Dhar, Arghya Kusum [1 ]
Mahesh, Radhakrishnan [1 ]
机构
[1] BITS, Dept Pharm, Pilani 333031, Rajasthan, India
关键词
Depression; 5-HT3 receptor antagonist; Forced swim test; Olfactory bulbectomy; PCPA; 1-(m-Chlorophenyl)-biguanide (mCPBG); OLFACTORY BULBECTOMIZED RAT; FORCED SWIMMING TEST; ANIMAL-MODELS; DEPRESSION; MICE; NOREPINEPHRINE; NEUROBIOLOGY; VENLAFAXINE; INHIBITOR; RELEASE;
D O I
10.1016/j.pbb.2013.05.006
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
The present study was designed to investigate the putative antidepressant-like activity of 7a, a 5-HT3 receptor antagonist, (although indirect evidence of 5-HT3 antagonism) with an optimal log P (3.35) and pA(2) value (7.6) greater than ondansetron (pA(2) - 6.6) using behavioural tests battery of depression. Acute treatment of 7a (0.5-2 mg/kg, i.p.) in mice produced antidepressant-like effects in forced swim test (FST) and tail suspension test (TST) without affecting the baseline locomotion in actophotometer test in mice. Moreover, the combination of a sub-effective dose of 7a (025 mg/kg, i.p.) and fluoxetine (5 mg/kg, i.p.) produced an anti-immobility effect in mouse FST. Pre-treatment of mice with p-chlorophenylalanine methyl ester (PCPA; 100 mg/kg, i.p., an inhibitor of serotonin (5-HT) synthesis, for 4 consecutive days) and 1-(m-Chlorophenyl)-biguanide (mCPBG, 10 mg/kg, i.p., a 5-HT3 receptor agonist) prevented the anti-immobility effects of 7a (2 mg/kg, i.p.) in the mouse PSI. In addition, 7a (0.5-2 mg/kg, i.p.) treatment also potentiated the 5-hydroxytryptophan (5-HTP) and pargyline induced head twitch response in mice. Furthermore, sub-chronic treatment (14 days) with 7a (0.5-2 mg/kg, i.p.) and paroxetine (10 mg/kg, i.p.) significantly attenuated the behavioural anomalies induced by bilateral olfactory bulbectomy in rats in a modified open field paradigm. These results suggest that the antidepressant-like action of 7a may be mediated by an interaction with the serotonergic system and this molecule should be further investigated as an alternative therapeutic approach for the treatment of depression. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:91 / 97
页数:7
相关论文
共 42 条
  • [31] STRUCTURE-ACTIVITY RELATIONSHIP STUDIES OF CENTRAL-NERVOUS-SYSTEM AGENTS .13. 4-[3-(BENZOTRIAZOL-1-YL)PROPYL]-1-(2-METHOXYPHENYL)PIPERAZINE, A NEW PUTATIVE 5-HT1A RECEPTOR ANTAGONIST, AND ITS ANALOGS
    MOKROSZ, JL
    PALUCHOWSKA, MH
    CHOJNACKAWOJCIK, E
    FILIP, M
    CHARAKCHIEVAMINOL, S
    DERENWESOLEK, A
    MOKROSZ, MJ
    JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (17) : 2754 - 2760
  • [32] Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3 carboxylic-acid
    Bleakman, D
    Schoepp, DD
    Ballyk, B
    Bufton, H
    Sharpe, EF
    Thomas, K
    Ornstein, PL
    Kamboj, RK
    MOLECULAR PHARMACOLOGY, 1996, 49 (04) : 581 - 585
  • [33] Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371•HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity
    Chappell, Mark D.
    Li, Renhua
    Smith, Stephon C.
    Dressman, Bruce A.
    Tromiczak, Eric G.
    Tripp, Allie E.
    Blanco, Maria-Jesus
    Vetman, Tatiana
    Quimby, Steven J.
    Matt, James
    Britton, Thomas C.
    Fivush, Adam M.
    Schkeryantz, Jeffrey M.
    Mayhugh, Daniel
    Erickson, Jon A.
    Bures, Mark G.
    Jaramillo, Carlos
    Carpintero, Mercedes
    Eugenio de Diego, Jose
    Barberis, Mario
    Garcia-Cerrada, Susana
    Soriano, Jose F.
    Antonysamy, Stephen
    Atwell, Shane
    MacEwan, Lain
    Condon, Bradley
    Sougias, Christine
    Wang, Jing
    Zhang, Aiping
    Conners, Kris
    Groshong, Chris
    Wasserman, Stephen R.
    Koss, John W.
    Witkin, Jeffrey M.
    Li, Xia
    Overshiner, Carl
    Wafford, Keith A.
    Seidel, Wesley
    Wang, Xu-Shan
    Heinz, Beverly A.
    Swanson, Steven
    Catlow, John T.
    Bedwell, David W.
    Monn, James A.
    Mitch, Charles H.
    Ornstein, Paul L.
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (24) : 10974 - 10993
  • [34] Characterization of the activity of L-ascorbic acid 2-[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl-hydrogen phosphate] potassium salt in hydroxyl radical elimination
    Tomita, T
    Kashima, M
    Tsujimoto, Y
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2000, 48 (03) : 330 - 333
  • [35] Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer
    El-Ahmad, Youssef
    Tabart, Michel
    Halley, Frank
    Certal, Victor
    Thompson, Fabienne
    Filoche-Romme, Bruno
    Gruss-Leleu, Florence
    Muller, Claire
    Brollo, Maurice
    Fabien, Laurence
    Loyau, Veronique
    Bertin, Luc
    Richepin, Patrick
    Pilorge, Fabienne
    Desmazeau, Pascal
    Girardet, Chrystelle
    Beccari, Sylvie
    Louboutin, Audrey
    Lebourg, Gilles
    Le -Roux, Jacques
    Terrier, Corinne
    Vallee, Francois
    Steier, Valerie
    Mathieu, Magali
    Rak, Alexey
    Abecassis, Pierre-Yves
    Vicat, Pascale
    Benard, Tsiala
    Bouaboula, Monsif
    Sun, Fangxian
    Shomali, Maysoun
    Hebert, Andrew
    Levit, Mikhail
    Cheng, Hong
    Courjaud, Albane
    Ginesty, Celine
    Perrault, Christelle
    Garcia-Echeverria, Carlos
    McCort, Gary
    Schiot, Laurent
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (02) : 512 - 528
  • [36] Design, Synthesis, and SAR of C-3 Benzoic Acid, C-17 Triterpenoid Derivatives. Identification of the HIV-1 Maturation Inhibitor 4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic Acid (GSK3532795, BMS-955176)
    Regueiro-Ren, Alicia
    Swidorski, Jacob J.
    Liu, Zheng
    Chen, Yan
    Sin, Ny
    Sit, Sing-Yuen
    Chen, Jie
    Venables, Brian L.
    Zhu, Juliang
    Nowicka-Sans, Beata
    Protack, Tricia
    Lin, Zeyu
    Terry, Brian
    Samanta, Himadri
    Zhang, Sharon
    Li, Zhufang
    Easter, John
    Beno, Brett R.
    Arora, Vinod
    Huang, Xiaohua S.
    Rahematpura, Sandhya
    Parker, Dawn D.
    Haskell, Roy
    Santone, Kenneth S.
    Cocket, Mark I.
    Krystal, Mark
    Meanwell, Nicholas A.
    Jenkins, Susan
    Hanumegowda, Umesh
    Dicker, Ira B.
    JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (16) : 7289 - 7313
  • [37] Discovery of 2-(2-Chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8-(5H)-one (PF-514273), a Novel, Bicyclic Lactam-Based Cannabinoid-1 Receptor Antagonist for the Treatment of Obesity
    Dow, Robert L.
    Carpino, Philip A.
    Hadcock, John R.
    Black, Shawn C.
    Iredale, Philip A.
    DaSilva-Jardine, Paul
    Schneider, Steven R.
    Paight, Ernest S.
    Griffith, David A.
    Scott, Dennis O.
    O'Connor, Rebecca E.
    Nduaka, Chudy I.
    JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (09) : 2652 - 2655
  • [38] INVITRO STUDIES ON THE INFLUENCE OF L-ASCORBIC-ACID 2-[3,4-DIHYDRO-2,5,7,8-TETRAMETHYL-2-(4,8,12-TRIMETHYLTRIDECYL)-2H-1-BENZOPYRAN-6YL-HYDROGEN PHOSPHATE] POTASSIUM-SALT ON LIPID-PEROXIDATION AND PHOSPHOLIPASE-A2 ACTIVITY
    KURIBAYASHI, Y
    YOSHIDA, K
    SAKAUE, T
    OKUMURA, A
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1992, 42-2 (09): : 1072 - 1074
  • [39] Serum protein binding of a novel β-lactam antibiotic, (+)-(6R, 7R)-7-[(Z)-2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3-N,N-dimethylcarbamoyloxymethyl-8-oxo-5-thia-1-azabicyclo[4.2.0.]oct-2-ene-2-carboxylic acid (E1100), and its effect on pharmacokinetics in rats
    Tokumura, T
    Horie, T
    STP PHARMA SCIENCES, 1998, 8 (04): : 261 - 266
  • [40] Development of (S)-N6-(2-(4-(Isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6, 7-tetrahydrobenzo[d]-thiazole-2,6-diamine and Its Analogue as a D3 Receptor Preferring Agonist: Potent in Vivo Activity in Parkinson's Disease Animal Models
    Ghosh, Balaram
    Antonio, Tamara
    Zhen, Juan
    Kharkar, Prashant
    Reith, Maarten E. A.
    Dutta, Aloke K.
    JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (03) : 1023 - 1037